General News ยท Pan-African
Fidson Selected to Manufacture Generic Influenza Antiviral Under Global Licence
By: Ola Badawy
Nigerian drugmaker Fidson has been chosen to manufacture a generic influenza antiviral under a global licence, signaling a significant expansion of production capabilities within Africa and potential impacts on regional access to treatment.
A Nigerian pharmaceutical company, Fidson Healthcare, has been selected to manufacture a generic influenza antiviral under a global licence. The arrangement is described as a generic production deal intended to increase access to influenza treatments across participating markets. Fidson, a long-established drugmaker in Nigeria, will utilize its manufacturing capabilities to produce the antiviral at scale, subject to regulatory approvals and quality assurance processes. The licence aims to support broader supply resilience for influenza therapeutics, particularly in African and other emerging markets, by leveraging local production. No further details on the specific antiviral, licensing terms, production timeline, or participating countries were provided in the source materials, and regulatory steps remain to be completed. Stakeholders will be watching for official confirmations from Fidson and related regulatory authorities regarding timelines, pricing, and distribution plans.